Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae : Contributions of Type II Topoisomerase Mutations and Efflux to Levels of Resistance
- 1 November 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (11) , 3049-3054
- https://doi.org/10.1128/aac.44.11.3049-3054.2000
Abstract
We report on amino acid substitutions in the quinolone resistance-determining region of type II topisomerases and the prevalence of reserpine-inhibited efflux for 70 clinical isolates ofS. pneumoniae for which the ciprofloxacin MIC is ≥4 μg/ml and 28 isolates for which the ciprofloxacin MIC is ≤2 μg/ml. The amino acid substitutions in ParC conferring low-level resistance (MICs, 4 to 8 μg/ml) included Phe, Tyr, and Ala for Ser-79; Asn, Ala, Gly, Tyr, and Val for Asp-83; Asn for Asp-78; and Pro for Ala-115. Isolates with intermediate-level (MICs, 16 to 32 μg/ml) and high-level (MICs, 64 μg/ml) resistance harbored substitutions of Phe and Tyr for Ser-79 or Asn and Ala for Asp-83 in ParC and an additional substitution in GyrA which included either Glu-85-Lys (Gly) or Ser-81-Phe (Tyr). Glu-85-Lys was found exclusively in isolates with high-level resistance. Efflux contributed primarily to low-level resistance in isolates with or without an amino acid substitution in ParC. The impact of amino acid substitutions in ParE was minimal, and no substitutions in GyrB were identified.Keywords
This publication has 44 references indexed in Scilit:
- Prevalence of gyrA , gyrB , parC , and parE Mutations in Clinical Isolates of Streptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory SeasonAntimicrobial Agents and Chemotherapy, 2000
- Contribution of Topoisomerase IV and DNA Gyrase Mutations in Streptococcus pneumoniae to Resistance to Novel FluoroquinolonesAntimicrobial Agents and Chemotherapy, 1999
- Decreased Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in CanadaNew England Journal of Medicine, 1999
- In Vitro Development of Resistance to Five Quinolones and Amoxicillin-Clavulanate in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1999
- Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands.Nature Structural & Molecular Biology, 1999
- Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae.Journal of Antimicrobial Chemotherapy, 1999
- ParC and GyrA May Be Interchangeable Initial Targets of Some Fluoroquinolones in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1999
- Primary Targets of Fluoroquinolones in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1999
- Community‐Acquired Pneumonia in Adults: Guidelines for ManagementClinical Infectious Diseases, 1998
- Community-Acquired PneumoniaNew England Journal of Medicine, 1995